Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
L Boiron, E Joura, N Largeron, B Prager… - BMC Infectious …, 2016 - Springer
Background HPV is a major cancer-causing factor in both sexes in the cervix, vulva, vagina,
anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts …
anus, penis, oropharynx as well as the causal factor in other diseases such as genital warts …
Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study
SM Matthijsse, JAC Hontelez, SK Naber… - The Journal of …, 2016 - academic.oup.com
Background. Expanding routine human papillomavirus (HPV) vaccination to adults could be
an effective strategy to improve prevention of HPV infection and cervical cancer. Methods …
an effective strategy to improve prevention of HPV infection and cervical cancer. Methods …
Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium
L Annemans, V Rémy, J Oyee, N Largeron - Pharmacoeconomics, 2009 - Springer
Background: The introduction of a quadrivalent human papillomavirus (HPV; types 6, 11, 16,
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …
18) vaccine is expected to significantly reduce the burden of cervical cancer, cervical …
Vaccination against human papillomavirus types 16 and 18: the impact on cervical cancer
J Berkhof, JA Bogaards - Future Oncology, 2010 - Taylor & Francis
Epidemiological studies have provided ample evidence that sexual partners are the source
of practically all incidences of genital HPV infections. The fact that HPV is sexually …
of practically all incidences of genital HPV infections. The fact that HPV is sexually …
[HTML][HTML] Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands
JJM Simons, N Vida, TA Westra, MJ Postma - Vaccine, 2020 - Elsevier
Background Vaccinating girls against human papillomavirus (HPV) infection is a highly
effective and cost-effective intervention to provide protection against HPV-induced cancers …
effective and cost-effective intervention to provide protection against HPV-induced cancers …
Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies
L Ribassin-Majed, R Lounes, S Clémençon - PloS one, 2012 - journals.plos.org
Background Seventy percent of sexually active individuals will be infected with Human
Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all …
Papillomavirus (HPV) during their lifetime. These infections are incriminated for almost all …
Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost–effectiveness analysis
X Bresse, C Goergen, B Prager… - Expert review of …, 2014 - Taylor & Francis
The International Agency for Research on Cancer acknowledges that HPV is a human
carcinogen affecting both sexes. This study aimed to evaluate the public health impact of …
carcinogen affecting both sexes. This study aimed to evaluate the public health impact of …
Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges
M Poljak - Clinical Microbiology and Infection, 2012 - Wiley Online Library
Clin Microbiol Infect 2012; 18 (Suppl. 5): 64–69 Abstract Two prophylactic human
papillomavirus (HPV) vaccines have been recently approved: one quadrivalent and the …
papillomavirus (HPV) vaccines have been recently approved: one quadrivalent and the …
Cost of preventing, managing, and treating human papillomavirus (HPV)-related diseases in Sweden before the introduction of quadrivalent HPV vaccination
E Östensson, M Fröberg, A Leval, AC Hellström… - PloS one, 2015 - journals.plos.org
Objective Costs associated with HPV-related diseases such as cervical dysplasia, cervical
cancer, and genital warts have not been evaluated in Sweden. These costs must be …
cancer, and genital warts have not been evaluated in Sweden. These costs must be …
Estimating the long-term effects of HPV vaccination in Germany
J Horn, O Damm, MEE Kretzschmar, Y Deleré… - Vaccine, 2013 - Elsevier
In Germany, vaccination against the most oncogenic HPV types 16/18 is recommended by
the Standing Committee on Vaccination (STIKO) for 12–17 year old girls since March 2007 …
the Standing Committee on Vaccination (STIKO) for 12–17 year old girls since March 2007 …